• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Merck & Co (NY:MRK)

    144.30 +0.49 (+0.34%)
    Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Merck & Co

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    News headline image
    3 of the Best ETFs to Buy and Hold if a Recession Is Coming ↗
    VHT, BND, and VOO could be your best bets in the next economic downturn. 
    Via The Motley Fool
    Topics ETFs Economy Regulatory Compliance
    What's going on in today's session: dow jones movers ↗
    Via Chartmill
    News headline image
    Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29
    From Merck & Co., Inc
    Via Business Wire
    Stay informed with the top movers within the dow jones index on Wednesday. ↗
    Via Chartmill
    News headline image
    Prediction: Moderna Stock Will Soar 100% by 2030 ↗
    The company could enter a fresh growth phase. 
    Via The Motley Fool
    News headline image
    2 Outstanding Dividend Stocks to Buy and Hold for a Decade ↗
    There is probably no dividend cut on the horizon for these healthcare companies. 
    Via The Motley Fool
    Topics Artificial Intelligence
    Uncover the latest developments among dow jones stocks in today's session. ↗
    Via Chartmill
    News headline image
    3 Healthcare Dividend Stocks Offering More Than Just Income ↗
    AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027. 
    Via MarketBeat
    News headline image
    Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
    From Merck & Co., Inc.
    Via Business Wire
    News headline image
    SCHD's Top Sector Bet Is Healthcare at 20.7%. I'm Not Sure What's More Surprising: What It Doesn't Hold, or What It Does. ↗
    SHCD is missing some of the healthiest dividend stocks. 
    Via The Motley Fool
    Topics ETFs Stocks
    News headline image
    3 Cash-Producing Stocks with Open Questions
    A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not... 
    Via StockStory
    Which dow jones stocks are moving on Tuesday? ↗
    Via Chartmill
    News headline image
    Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks
    Looking back on branded pharmaceuticals stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Merck (NYSE:MRK) and its peers. L... 
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D (ON) Inhibitor
    From Merck & Co., Inc.
    Via Business Wire
    Friday's session: top gainers and losers in the dow jones index ↗
    Via Chartmill
    News headline image
    U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
    From Merck & Co., Inc.
    Via Business Wire
    Stay informed with the top movers within the dow jones index on Thursday. ↗
    Via Chartmill
    Thursday's session: top gainers and losers in the dow jones index ↗
    Via Chartmill
    News headline image
    Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
    From Merck & Co.
    Via Business Wire
    Wednesday's session: top gainers and losers in the dow jones index ↗
    Via Chartmill
    Stay informed with the top movers within the dow jones index on Wednesday. ↗
    Via Chartmill
    News headline image
    3 Healthcare Stocks with Warning Signs
    From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry... 
    Via StockStory
    Tuesday's session: top gainers and losers in the dow jones index ↗
    Via Chartmill
    Uncover the latest developments among dow jones stocks in today's session. ↗
    Via Chartmill
    News headline image
    U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
    From Merck & Co., Inc.
    Via Business Wire
    Meta's Muse Sends the Nasdaq to a Record and Rekindles the AI Trade ↗
    Via Chartmill
    Topics Artificial Intelligence
    News headline image
    BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline? ↗
    Investors buying this biotech stock now will get its pipeline essentially for free. 
    Via The Motley Fool
    News headline image
    3 Reasons to Sell MRK and 1 Stock to Buy Instead
    Over the past six months, Merck has been a great trade, beating the S&P 500 by 13.4%. Its stock price has climbed to $149.98, representing a healthy 29.6% in... 
    Via StockStory
    Topics Stocks
    These dow jones stocks are moving in today's session ↗
    Via Chartmill
    Discover which dow jones stocks are making waves on Monday. ↗
    Via Chartmill
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.